"Trading on OTCQX International will provide enhanced access to U.S. investors and the ability for DiagnoCure to diversify its shareholder base," said Chantal Miklosi, Chief Financial Officer of DiagnoCure. "We believe that trading on the OTCQX marketplace is in the best interest of shareholders and will enable the Company to enhance the market liquidity of DiagnoCure shares."About DiagnoCure DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage TM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com. Forward‐looking statements This release contains "forward‐looking statements," within the meaning of applicable United States and Canadian securities laws, that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. Such forward-looking statements include the outcome of research and development projects, clinical studies, future revenues, the benefits of being quoted on the OTCQX and the improved liquidity of the Company's shares when traded on the OTCQX and are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations. SOURCE DiagnoCure inc.